Barriers to the Use of Medications to Treat Alcoholism
In 1994, naltrexone became the first medication approved by the Food and Drug Administration as an adjunct in alcoholism treatment in almost fifty years. Despite evidence of its efficacy, use of naltrexone is not widespread. Patient and physician focus groups were used to identify reasons naltrexone...
Gespeichert in:
| Veröffentlicht in: | The American journal on addictions 2003-07, Vol.12 (4), p.281-294 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 294 |
|---|---|
| container_issue | 4 |
| container_start_page | 281 |
| container_title | The American journal on addictions |
| container_volume | 12 |
| creator | Mark, Tami L. Kranzler, Henry R. Poole, Virginia H. Hagen, Carol A. McLeod, Caroline Crosse, Scott |
| description | In 1994, naltrexone became the first medication approved by the Food and Drug Administration as an adjunct in alcoholism treatment in almost fifty years. Despite evidence of its efficacy, use of naltrexone is not widespread. Patient and physician focus groups were used to identify reasons naltrexone has not been prescribed more widely. Barriers to its widespread use include a lack of awareness, a lack of evidence of efficacy in practice, side effects, time for patient management, a reluctance to take medications, medication addiction concerns, Alcoholics Anonymous (AA) philosophy, and price. The study indicates that medications to treat alcoholism must overcome numerous barriers before becoming widely accepted. (Am J Addict 2003;12:281-294) |
| doi_str_mv | 10.1080/10550490390226879 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19614899</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19614899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c312t-10d09cdc6806eec34b41e5f9dbd57a25a5e7ef3cb0e4d17ec256b75429d0b3353</originalsourceid><addsrcrecordid>eNp9kD9PwzAQxS0EolD4ACwoE1vA58ROLKZS8U8qYmnnyLEvSqokLrYz8O0xtBIDErfc6e73nnSPkCugt0BLegeUc5pLmknKmCgLeUTOgDNI4waO4xzvaQTEjJx7v6WxSilOyQzyqKMMzoh4UM516HwSbBJaTDYeE9skb2g6rUJnx5_L2qEKyaLXtrV954cLctKo3uPloc_J5ulxvXxJV-_Pr8vFKtUZsJACNVRqo0VJBaLO8joH5I00teGFYlxxLLDJdE0xN1CgZlzUBc-ZNLTOMp7Nyc3ed-fsx4Q-VEPnNfa9GtFOvgIpIC-ljCDsQe2s9w6baue6QbnPCmj1HVb1J6youT6YT_WA5ldxSCcC93ugGxvrBtWi6kOrlcNqayc3xs__sf8Ccip1mQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19614899</pqid></control><display><type>article</type><title>Barriers to the Use of Medications to Treat Alcoholism</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Taylor & Francis Journals Complete</source><creator>Mark, Tami L. ; Kranzler, Henry R. ; Poole, Virginia H. ; Hagen, Carol A. ; McLeod, Caroline ; Crosse, Scott</creator><creatorcontrib>Mark, Tami L. ; Kranzler, Henry R. ; Poole, Virginia H. ; Hagen, Carol A. ; McLeod, Caroline ; Crosse, Scott</creatorcontrib><description>In 1994, naltrexone became the first medication approved by the Food and Drug Administration as an adjunct in alcoholism treatment in almost fifty years. Despite evidence of its efficacy, use of naltrexone is not widespread. Patient and physician focus groups were used to identify reasons naltrexone has not been prescribed more widely. Barriers to its widespread use include a lack of awareness, a lack of evidence of efficacy in practice, side effects, time for patient management, a reluctance to take medications, medication addiction concerns, Alcoholics Anonymous (AA) philosophy, and price. The study indicates that medications to treat alcoholism must overcome numerous barriers before becoming widely accepted. (Am J Addict 2003;12:281-294)</description><identifier>ISSN: 1055-0496</identifier><identifier>EISSN: 1521-0391</identifier><identifier>DOI: 10.1080/10550490390226879</identifier><identifier>PMID: 14504021</identifier><language>eng</language><publisher>England: Informa UK Ltd</publisher><subject>Alcoholism - economics ; Alcoholism - rehabilitation ; Attitude of Health Personnel ; Cost-Benefit Analysis ; Drug Approval ; Focus Groups ; Humans ; Naltrexone - adverse effects ; Naltrexone - economics ; Naltrexone - therapeutic use ; Narcotic Antagonists - adverse effects ; Narcotic Antagonists - economics ; Narcotic Antagonists - therapeutic use ; Patient Acceptance of Health Care ; Treatment Outcome ; United States</subject><ispartof>The American journal on addictions, 2003-07, Vol.12 (4), p.281-294</ispartof><rights>2003 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c312t-10d09cdc6806eec34b41e5f9dbd57a25a5e7ef3cb0e4d17ec256b75429d0b3353</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/10550490390226879$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/10550490390226879$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,61221,61402</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14504021$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mark, Tami L.</creatorcontrib><creatorcontrib>Kranzler, Henry R.</creatorcontrib><creatorcontrib>Poole, Virginia H.</creatorcontrib><creatorcontrib>Hagen, Carol A.</creatorcontrib><creatorcontrib>McLeod, Caroline</creatorcontrib><creatorcontrib>Crosse, Scott</creatorcontrib><title>Barriers to the Use of Medications to Treat Alcoholism</title><title>The American journal on addictions</title><addtitle>Am J Addict</addtitle><description>In 1994, naltrexone became the first medication approved by the Food and Drug Administration as an adjunct in alcoholism treatment in almost fifty years. Despite evidence of its efficacy, use of naltrexone is not widespread. Patient and physician focus groups were used to identify reasons naltrexone has not been prescribed more widely. Barriers to its widespread use include a lack of awareness, a lack of evidence of efficacy in practice, side effects, time for patient management, a reluctance to take medications, medication addiction concerns, Alcoholics Anonymous (AA) philosophy, and price. The study indicates that medications to treat alcoholism must overcome numerous barriers before becoming widely accepted. (Am J Addict 2003;12:281-294)</description><subject>Alcoholism - economics</subject><subject>Alcoholism - rehabilitation</subject><subject>Attitude of Health Personnel</subject><subject>Cost-Benefit Analysis</subject><subject>Drug Approval</subject><subject>Focus Groups</subject><subject>Humans</subject><subject>Naltrexone - adverse effects</subject><subject>Naltrexone - economics</subject><subject>Naltrexone - therapeutic use</subject><subject>Narcotic Antagonists - adverse effects</subject><subject>Narcotic Antagonists - economics</subject><subject>Narcotic Antagonists - therapeutic use</subject><subject>Patient Acceptance of Health Care</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>1055-0496</issn><issn>1521-0391</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kD9PwzAQxS0EolD4ACwoE1vA58ROLKZS8U8qYmnnyLEvSqokLrYz8O0xtBIDErfc6e73nnSPkCugt0BLegeUc5pLmknKmCgLeUTOgDNI4waO4xzvaQTEjJx7v6WxSilOyQzyqKMMzoh4UM516HwSbBJaTDYeE9skb2g6rUJnx5_L2qEKyaLXtrV954cLctKo3uPloc_J5ulxvXxJV-_Pr8vFKtUZsJACNVRqo0VJBaLO8joH5I00teGFYlxxLLDJdE0xN1CgZlzUBc-ZNLTOMp7Nyc3ed-fsx4Q-VEPnNfa9GtFOvgIpIC-ljCDsQe2s9w6baue6QbnPCmj1HVb1J6youT6YT_WA5ldxSCcC93ugGxvrBtWi6kOrlcNqayc3xs__sf8Ccip1mQ</recordid><startdate>20030701</startdate><enddate>20030701</enddate><creator>Mark, Tami L.</creator><creator>Kranzler, Henry R.</creator><creator>Poole, Virginia H.</creator><creator>Hagen, Carol A.</creator><creator>McLeod, Caroline</creator><creator>Crosse, Scott</creator><general>Informa UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>20030701</creationdate><title>Barriers to the Use of Medications to Treat Alcoholism</title><author>Mark, Tami L. ; Kranzler, Henry R. ; Poole, Virginia H. ; Hagen, Carol A. ; McLeod, Caroline ; Crosse, Scott</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c312t-10d09cdc6806eec34b41e5f9dbd57a25a5e7ef3cb0e4d17ec256b75429d0b3353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Alcoholism - economics</topic><topic>Alcoholism - rehabilitation</topic><topic>Attitude of Health Personnel</topic><topic>Cost-Benefit Analysis</topic><topic>Drug Approval</topic><topic>Focus Groups</topic><topic>Humans</topic><topic>Naltrexone - adverse effects</topic><topic>Naltrexone - economics</topic><topic>Naltrexone - therapeutic use</topic><topic>Narcotic Antagonists - adverse effects</topic><topic>Narcotic Antagonists - economics</topic><topic>Narcotic Antagonists - therapeutic use</topic><topic>Patient Acceptance of Health Care</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mark, Tami L.</creatorcontrib><creatorcontrib>Kranzler, Henry R.</creatorcontrib><creatorcontrib>Poole, Virginia H.</creatorcontrib><creatorcontrib>Hagen, Carol A.</creatorcontrib><creatorcontrib>McLeod, Caroline</creatorcontrib><creatorcontrib>Crosse, Scott</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>The American journal on addictions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mark, Tami L.</au><au>Kranzler, Henry R.</au><au>Poole, Virginia H.</au><au>Hagen, Carol A.</au><au>McLeod, Caroline</au><au>Crosse, Scott</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Barriers to the Use of Medications to Treat Alcoholism</atitle><jtitle>The American journal on addictions</jtitle><addtitle>Am J Addict</addtitle><date>2003-07-01</date><risdate>2003</risdate><volume>12</volume><issue>4</issue><spage>281</spage><epage>294</epage><pages>281-294</pages><issn>1055-0496</issn><eissn>1521-0391</eissn><abstract>In 1994, naltrexone became the first medication approved by the Food and Drug Administration as an adjunct in alcoholism treatment in almost fifty years. Despite evidence of its efficacy, use of naltrexone is not widespread. Patient and physician focus groups were used to identify reasons naltrexone has not been prescribed more widely. Barriers to its widespread use include a lack of awareness, a lack of evidence of efficacy in practice, side effects, time for patient management, a reluctance to take medications, medication addiction concerns, Alcoholics Anonymous (AA) philosophy, and price. The study indicates that medications to treat alcoholism must overcome numerous barriers before becoming widely accepted. (Am J Addict 2003;12:281-294)</abstract><cop>England</cop><pub>Informa UK Ltd</pub><pmid>14504021</pmid><doi>10.1080/10550490390226879</doi><tpages>14</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1055-0496 |
| ispartof | The American journal on addictions, 2003-07, Vol.12 (4), p.281-294 |
| issn | 1055-0496 1521-0391 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19614899 |
| source | MEDLINE; Access via Wiley Online Library; Taylor & Francis Journals Complete |
| subjects | Alcoholism - economics Alcoholism - rehabilitation Attitude of Health Personnel Cost-Benefit Analysis Drug Approval Focus Groups Humans Naltrexone - adverse effects Naltrexone - economics Naltrexone - therapeutic use Narcotic Antagonists - adverse effects Narcotic Antagonists - economics Narcotic Antagonists - therapeutic use Patient Acceptance of Health Care Treatment Outcome United States |
| title | Barriers to the Use of Medications to Treat Alcoholism |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T13%3A37%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Barriers%20to%20the%20Use%20of%20Medications%20to%20Treat%20Alcoholism&rft.jtitle=The%20American%20journal%20on%20addictions&rft.au=Mark,%20Tami%20L.&rft.date=2003-07-01&rft.volume=12&rft.issue=4&rft.spage=281&rft.epage=294&rft.pages=281-294&rft.issn=1055-0496&rft.eissn=1521-0391&rft_id=info:doi/10.1080/10550490390226879&rft_dat=%3Cproquest_cross%3E19614899%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19614899&rft_id=info:pmid/14504021&rfr_iscdi=true |